Last week the specialist drug development Company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases provided a trading update ahead of its full year results for the year ended 30 June 2020. In the same week, Sareum also hosted an online presentation for investors, highlighting that its development activity is now 100% focused on the development of its proprietary TYK2/JAK1 inhibitors where Sareum is continuing initial discussions with p
18 Aug 2020
Well funded to focus energies on partnering activities for TYK2/JAK1 Inhibitors
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Well funded to focus energies on partnering activities for TYK2/JAK1 Inhibitors
Sareum Holdings plc (SAR:LON) | 30.5 -0.9 (-9.0%) | Mkt Cap: 31.0m
- Published:
18 Aug 2020 -
Author:
Derren Nathan -
Pages:
9
Last week the specialist drug development Company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases provided a trading update ahead of its full year results for the year ended 30 June 2020. In the same week, Sareum also hosted an online presentation for investors, highlighting that its development activity is now 100% focused on the development of its proprietary TYK2/JAK1 inhibitors where Sareum is continuing initial discussions with p